Global Castration-resistant Prostate Cancer Drugs Market 2025 by Company, Regions, Type and Application, Forecast to 2031
According to our (Global Info Research) latest study, the global Castration-resistant Prostate Cancer Drugs market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Castration-resistant Prostate Cancer Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Castration-resistant Prostate Cancer Drugs market size and forecasts, in consumption value ($ Million), 2020-2031
Global Castration-resistant Prostate Cancer Drugs market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Castration-resistant Prostate Cancer Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Castration-resistant Prostate Cancer Drugs market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Castration-resistant Prostate Cancer Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Castration-resistant Prostate Cancer Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Astellas, Janssen, AstraZeneca, Bayer, Hengrui, CTTQ, Sanofi, Hansoh, Clovis Oncology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Castration-resistant Prostate Cancer Drugs market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Castration-resistant Prostate Cancer Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Castration-resistant Prostate Cancer Drugs, with revenue, gross margin, and global market share of Castration-resistant Prostate Cancer Drugs from 2020 to 2025.
Chapter 3, the Castration-resistant Prostate Cancer Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Castration-resistant Prostate Cancer Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Castration-resistant Prostate Cancer Drugs.
Chapter 13, to describe Castration-resistant Prostate Cancer Drugs research findings and conclusion.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Castration-resistant Prostate Cancer Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Castration-resistant Prostate Cancer Drugs market size and forecasts, in consumption value ($ Million), 2020-2031
Global Castration-resistant Prostate Cancer Drugs market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Castration-resistant Prostate Cancer Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Castration-resistant Prostate Cancer Drugs market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Castration-resistant Prostate Cancer Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Castration-resistant Prostate Cancer Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Astellas, Janssen, AstraZeneca, Bayer, Hengrui, CTTQ, Sanofi, Hansoh, Clovis Oncology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Castration-resistant Prostate Cancer Drugs market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Oral
- Intravenous Injection
- Others
- Hospital
- Specialty Clinic
- Others
- Pfizer
- Astellas
- Janssen
- AstraZeneca
- Bayer
- Hengrui
- CTTQ
- Sanofi
- Hansoh
- Clovis Oncology
- Zhendong Pharmaceutical
- Merck
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Castration-resistant Prostate Cancer Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Castration-resistant Prostate Cancer Drugs, with revenue, gross margin, and global market share of Castration-resistant Prostate Cancer Drugs from 2020 to 2025.
Chapter 3, the Castration-resistant Prostate Cancer Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Castration-resistant Prostate Cancer Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Castration-resistant Prostate Cancer Drugs.
Chapter 13, to describe Castration-resistant Prostate Cancer Drugs research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Castration-resistant Prostate Cancer Drugs by Type
1.3.1 Overview: Global Castration-resistant Prostate Cancer Drugs Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Type in 2024
1.3.3 Oral
1.3.4 Intravenous Injection
1.3.5 Others
1.4 Global Castration-resistant Prostate Cancer Drugs Market by Application
1.4.1 Overview: Global Castration-resistant Prostate Cancer Drugs Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital
1.4.3 Specialty Clinic
1.4.4 Others
1.5 Global Castration-resistant Prostate Cancer Drugs Market Size & Forecast
1.6 Global Castration-resistant Prostate Cancer Drugs Market Size and Forecast by Region
1.6.1 Global Castration-resistant Prostate Cancer Drugs Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Castration-resistant Prostate Cancer Drugs Market Size by Region, (2020-2031)
1.6.3 North America Castration-resistant Prostate Cancer Drugs Market Size and Prospect (2020-2031)
1.6.4 Europe Castration-resistant Prostate Cancer Drugs Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size and Prospect (2020-2031)
1.6.6 South America Castration-resistant Prostate Cancer Drugs Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Size and Prospect (2020-2031)
2 COMPANY PROFILES
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Castration-resistant Prostate Cancer Drugs Product and Solutions
2.1.4 Pfizer Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 Astellas
2.2.1 Astellas Details
2.2.2 Astellas Major Business
2.2.3 Astellas Castration-resistant Prostate Cancer Drugs Product and Solutions
2.2.4 Astellas Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Astellas Recent Developments and Future Plans
2.3 Janssen
2.3.1 Janssen Details
2.3.2 Janssen Major Business
2.3.3 Janssen Castration-resistant Prostate Cancer Drugs Product and Solutions
2.3.4 Janssen Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Janssen Recent Developments and Future Plans
2.4 AstraZeneca
2.4.1 AstraZeneca Details
2.4.2 AstraZeneca Major Business
2.4.3 AstraZeneca Castration-resistant Prostate Cancer Drugs Product and Solutions
2.4.4 AstraZeneca Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 AstraZeneca Recent Developments and Future Plans
2.5 Bayer
2.5.1 Bayer Details
2.5.2 Bayer Major Business
2.5.3 Bayer Castration-resistant Prostate Cancer Drugs Product and Solutions
2.5.4 Bayer Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Bayer Recent Developments and Future Plans
2.6 Hengrui
2.6.1 Hengrui Details
2.6.2 Hengrui Major Business
2.6.3 Hengrui Castration-resistant Prostate Cancer Drugs Product and Solutions
2.6.4 Hengrui Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Hengrui Recent Developments and Future Plans
2.7 CTTQ
2.7.1 CTTQ Details
2.7.2 CTTQ Major Business
2.7.3 CTTQ Castration-resistant Prostate Cancer Drugs Product and Solutions
2.7.4 CTTQ Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 CTTQ Recent Developments and Future Plans
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Castration-resistant Prostate Cancer Drugs Product and Solutions
2.8.4 Sanofi Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Sanofi Recent Developments and Future Plans
2.9 Hansoh
2.9.1 Hansoh Details
2.9.2 Hansoh Major Business
2.9.3 Hansoh Castration-resistant Prostate Cancer Drugs Product and Solutions
2.9.4 Hansoh Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Hansoh Recent Developments and Future Plans
2.10 Clovis Oncology
2.10.1 Clovis Oncology Details
2.10.2 Clovis Oncology Major Business
2.10.3 Clovis Oncology Castration-resistant Prostate Cancer Drugs Product and Solutions
2.10.4 Clovis Oncology Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Clovis Oncology Recent Developments and Future Plans
2.11 Zhendong Pharmaceutical
2.11.1 Zhendong Pharmaceutical Details
2.11.2 Zhendong Pharmaceutical Major Business
2.11.3 Zhendong Pharmaceutical Castration-resistant Prostate Cancer Drugs Product and Solutions
2.11.4 Zhendong Pharmaceutical Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 Zhendong Pharmaceutical Recent Developments and Future Plans
2.12 Merck
2.12.1 Merck Details
2.12.2 Merck Major Business
2.12.3 Merck Castration-resistant Prostate Cancer Drugs Product and Solutions
2.12.4 Merck Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.12.5 Merck Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Castration-resistant Prostate Cancer Drugs Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Castration-resistant Prostate Cancer Drugs by Company Revenue
3.2.2 Top 3 Castration-resistant Prostate Cancer Drugs Players Market Share in 2024
3.2.3 Top 6 Castration-resistant Prostate Cancer Drugs Players Market Share in 2024
3.3 Castration-resistant Prostate Cancer Drugs Market: Overall Company Footprint Analysis
3.3.1 Castration-resistant Prostate Cancer Drugs Market: Region Footprint
3.3.2 Castration-resistant Prostate Cancer Drugs Market: Company Product Type Footprint
3.3.3 Castration-resistant Prostate Cancer Drugs Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Castration-resistant Prostate Cancer Drugs Consumption Value and Market Share by Type (2020-2025)
4.2 Global Castration-resistant Prostate Cancer Drugs Market Forecast by Type (2026-2031)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Application (2020-2025)
5.2 Global Castration-resistant Prostate Cancer Drugs Market Forecast by Application (2026-2031)
6 NORTH AMERICA
6.1 North America Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2031)
6.2 North America Castration-resistant Prostate Cancer Drugs Market Size by Application (2020-2031)
6.3 North America Castration-resistant Prostate Cancer Drugs Market Size by Country
6.3.1 North America Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2020-2031)
6.3.2 United States Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
6.3.3 Canada Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
6.3.4 Mexico Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
7 EUROPE
7.1 Europe Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2031)
7.2 Europe Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2031)
7.3 Europe Castration-resistant Prostate Cancer Drugs Market Size by Country
7.3.1 Europe Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2020-2031)
7.3.2 Germany Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
7.3.3 France Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
7.3.5 Russia Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
7.3.6 Italy Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
8 ASIA-PACIFIC
8.1 Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size by Region
8.3.1 Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value by Region (2020-2031)
8.3.2 China Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
8.3.3 Japan Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
8.3.4 South Korea Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
8.3.5 India Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
8.3.7 Australia Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
9 SOUTH AMERICA
9.1 South America Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2031)
9.2 South America Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2031)
9.3 South America Castration-resistant Prostate Cancer Drugs Market Size by Country
9.3.1 South America Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2020-2031)
9.3.2 Brazil Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
9.3.3 Argentina Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Size by Country
10.3.1 Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2020-2031)
10.3.2 Turkey Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
10.3.4 UAE Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
11 MARKET DYNAMICS
11.1 Castration-resistant Prostate Cancer Drugs Market Drivers
11.2 Castration-resistant Prostate Cancer Drugs Market Restraints
11.3 Castration-resistant Prostate Cancer Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Castration-resistant Prostate Cancer Drugs Industry Chain
12.2 Castration-resistant Prostate Cancer Drugs Upstream Analysis
12.3 Castration-resistant Prostate Cancer Drugs Midstream Analysis
12.4 Castration-resistant Prostate Cancer Drugs Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Castration-resistant Prostate Cancer Drugs by Type
1.3.1 Overview: Global Castration-resistant Prostate Cancer Drugs Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Type in 2024
1.3.3 Oral
1.3.4 Intravenous Injection
1.3.5 Others
1.4 Global Castration-resistant Prostate Cancer Drugs Market by Application
1.4.1 Overview: Global Castration-resistant Prostate Cancer Drugs Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital
1.4.3 Specialty Clinic
1.4.4 Others
1.5 Global Castration-resistant Prostate Cancer Drugs Market Size & Forecast
1.6 Global Castration-resistant Prostate Cancer Drugs Market Size and Forecast by Region
1.6.1 Global Castration-resistant Prostate Cancer Drugs Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Castration-resistant Prostate Cancer Drugs Market Size by Region, (2020-2031)
1.6.3 North America Castration-resistant Prostate Cancer Drugs Market Size and Prospect (2020-2031)
1.6.4 Europe Castration-resistant Prostate Cancer Drugs Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size and Prospect (2020-2031)
1.6.6 South America Castration-resistant Prostate Cancer Drugs Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Size and Prospect (2020-2031)
2 COMPANY PROFILES
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Castration-resistant Prostate Cancer Drugs Product and Solutions
2.1.4 Pfizer Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 Astellas
2.2.1 Astellas Details
2.2.2 Astellas Major Business
2.2.3 Astellas Castration-resistant Prostate Cancer Drugs Product and Solutions
2.2.4 Astellas Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Astellas Recent Developments and Future Plans
2.3 Janssen
2.3.1 Janssen Details
2.3.2 Janssen Major Business
2.3.3 Janssen Castration-resistant Prostate Cancer Drugs Product and Solutions
2.3.4 Janssen Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Janssen Recent Developments and Future Plans
2.4 AstraZeneca
2.4.1 AstraZeneca Details
2.4.2 AstraZeneca Major Business
2.4.3 AstraZeneca Castration-resistant Prostate Cancer Drugs Product and Solutions
2.4.4 AstraZeneca Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 AstraZeneca Recent Developments and Future Plans
2.5 Bayer
2.5.1 Bayer Details
2.5.2 Bayer Major Business
2.5.3 Bayer Castration-resistant Prostate Cancer Drugs Product and Solutions
2.5.4 Bayer Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Bayer Recent Developments and Future Plans
2.6 Hengrui
2.6.1 Hengrui Details
2.6.2 Hengrui Major Business
2.6.3 Hengrui Castration-resistant Prostate Cancer Drugs Product and Solutions
2.6.4 Hengrui Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Hengrui Recent Developments and Future Plans
2.7 CTTQ
2.7.1 CTTQ Details
2.7.2 CTTQ Major Business
2.7.3 CTTQ Castration-resistant Prostate Cancer Drugs Product and Solutions
2.7.4 CTTQ Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 CTTQ Recent Developments and Future Plans
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Castration-resistant Prostate Cancer Drugs Product and Solutions
2.8.4 Sanofi Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Sanofi Recent Developments and Future Plans
2.9 Hansoh
2.9.1 Hansoh Details
2.9.2 Hansoh Major Business
2.9.3 Hansoh Castration-resistant Prostate Cancer Drugs Product and Solutions
2.9.4 Hansoh Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Hansoh Recent Developments and Future Plans
2.10 Clovis Oncology
2.10.1 Clovis Oncology Details
2.10.2 Clovis Oncology Major Business
2.10.3 Clovis Oncology Castration-resistant Prostate Cancer Drugs Product and Solutions
2.10.4 Clovis Oncology Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Clovis Oncology Recent Developments and Future Plans
2.11 Zhendong Pharmaceutical
2.11.1 Zhendong Pharmaceutical Details
2.11.2 Zhendong Pharmaceutical Major Business
2.11.3 Zhendong Pharmaceutical Castration-resistant Prostate Cancer Drugs Product and Solutions
2.11.4 Zhendong Pharmaceutical Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 Zhendong Pharmaceutical Recent Developments and Future Plans
2.12 Merck
2.12.1 Merck Details
2.12.2 Merck Major Business
2.12.3 Merck Castration-resistant Prostate Cancer Drugs Product and Solutions
2.12.4 Merck Castration-resistant Prostate Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.12.5 Merck Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Castration-resistant Prostate Cancer Drugs Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Castration-resistant Prostate Cancer Drugs by Company Revenue
3.2.2 Top 3 Castration-resistant Prostate Cancer Drugs Players Market Share in 2024
3.2.3 Top 6 Castration-resistant Prostate Cancer Drugs Players Market Share in 2024
3.3 Castration-resistant Prostate Cancer Drugs Market: Overall Company Footprint Analysis
3.3.1 Castration-resistant Prostate Cancer Drugs Market: Region Footprint
3.3.2 Castration-resistant Prostate Cancer Drugs Market: Company Product Type Footprint
3.3.3 Castration-resistant Prostate Cancer Drugs Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Castration-resistant Prostate Cancer Drugs Consumption Value and Market Share by Type (2020-2025)
4.2 Global Castration-resistant Prostate Cancer Drugs Market Forecast by Type (2026-2031)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Application (2020-2025)
5.2 Global Castration-resistant Prostate Cancer Drugs Market Forecast by Application (2026-2031)
6 NORTH AMERICA
6.1 North America Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2031)
6.2 North America Castration-resistant Prostate Cancer Drugs Market Size by Application (2020-2031)
6.3 North America Castration-resistant Prostate Cancer Drugs Market Size by Country
6.3.1 North America Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2020-2031)
6.3.2 United States Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
6.3.3 Canada Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
6.3.4 Mexico Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
7 EUROPE
7.1 Europe Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2031)
7.2 Europe Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2031)
7.3 Europe Castration-resistant Prostate Cancer Drugs Market Size by Country
7.3.1 Europe Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2020-2031)
7.3.2 Germany Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
7.3.3 France Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
7.3.5 Russia Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
7.3.6 Italy Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
8 ASIA-PACIFIC
8.1 Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size by Region
8.3.1 Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value by Region (2020-2031)
8.3.2 China Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
8.3.3 Japan Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
8.3.4 South Korea Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
8.3.5 India Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
8.3.7 Australia Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
9 SOUTH AMERICA
9.1 South America Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2031)
9.2 South America Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2031)
9.3 South America Castration-resistant Prostate Cancer Drugs Market Size by Country
9.3.1 South America Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2020-2031)
9.3.2 Brazil Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
9.3.3 Argentina Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Size by Country
10.3.1 Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2020-2031)
10.3.2 Turkey Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
10.3.4 UAE Castration-resistant Prostate Cancer Drugs Market Size and Forecast (2020-2031)
11 MARKET DYNAMICS
11.1 Castration-resistant Prostate Cancer Drugs Market Drivers
11.2 Castration-resistant Prostate Cancer Drugs Market Restraints
11.3 Castration-resistant Prostate Cancer Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Castration-resistant Prostate Cancer Drugs Industry Chain
12.2 Castration-resistant Prostate Cancer Drugs Upstream Analysis
12.3 Castration-resistant Prostate Cancer Drugs Midstream Analysis
12.4 Castration-resistant Prostate Cancer Drugs Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF FIGURES
Table 1. Global Castration-resistant Prostate Cancer Drugs Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Castration-resistant Prostate Cancer Drugs Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Global Castration-resistant Prostate Cancer Drugs Consumption Value by Region (2020-2025) & (USD Million)
Table 4. Global Castration-resistant Prostate Cancer Drugs Consumption Value by Region (2026-2031) & (USD Million)
Table 5. Pfizer Company Information, Head Office, and Major Competitors
Table 6. Pfizer Major Business
Table 7. Pfizer Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 8. Pfizer Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 9. Pfizer Recent Developments and Future Plans
Table 10. Astellas Company Information, Head Office, and Major Competitors
Table 11. Astellas Major Business
Table 12. Astellas Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 13. Astellas Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 14. Astellas Recent Developments and Future Plans
Table 15. Janssen Company Information, Head Office, and Major Competitors
Table 16. Janssen Major Business
Table 17. Janssen Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 18. Janssen Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 19. AstraZeneca Company Information, Head Office, and Major Competitors
Table 20. AstraZeneca Major Business
Table 21. AstraZeneca Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 22. AstraZeneca Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 23. AstraZeneca Recent Developments and Future Plans
Table 24. Bayer Company Information, Head Office, and Major Competitors
Table 25. Bayer Major Business
Table 26. Bayer Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 27. Bayer Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 28. Bayer Recent Developments and Future Plans
Table 29. Hengrui Company Information, Head Office, and Major Competitors
Table 30. Hengrui Major Business
Table 31. Hengrui Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 32. Hengrui Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 33. Hengrui Recent Developments and Future Plans
Table 34. CTTQ Company Information, Head Office, and Major Competitors
Table 35. CTTQ Major Business
Table 36. CTTQ Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 37. CTTQ Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 38. CTTQ Recent Developments and Future Plans
Table 39. Sanofi Company Information, Head Office, and Major Competitors
Table 40. Sanofi Major Business
Table 41. Sanofi Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 42. Sanofi Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 43. Sanofi Recent Developments and Future Plans
Table 44. Hansoh Company Information, Head Office, and Major Competitors
Table 45. Hansoh Major Business
Table 46. Hansoh Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 47. Hansoh Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 48. Hansoh Recent Developments and Future Plans
Table 49. Clovis Oncology Company Information, Head Office, and Major Competitors
Table 50. Clovis Oncology Major Business
Table 51. Clovis Oncology Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 52. Clovis Oncology Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 53. Clovis Oncology Recent Developments and Future Plans
Table 54. Zhendong Pharmaceutical Company Information, Head Office, and Major Competitors
Table 55. Zhendong Pharmaceutical Major Business
Table 56. Zhendong Pharmaceutical Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 57. Zhendong Pharmaceutical Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 58. Zhendong Pharmaceutical Recent Developments and Future Plans
Table 59. Merck Company Information, Head Office, and Major Competitors
Table 60. Merck Major Business
Table 61. Merck Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 62. Merck Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 63. Merck Recent Developments and Future Plans
Table 64. Global Castration-resistant Prostate Cancer Drugs Revenue (USD Million) by Players (2020-2025)
Table 65. Global Castration-resistant Prostate Cancer Drugs Revenue Share by Players (2020-2025)
Table 66. Breakdown of Castration-resistant Prostate Cancer Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
Table 67. Market Position of Players in Castration-resistant Prostate Cancer Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 68. Head Office of Key Castration-resistant Prostate Cancer Drugs Players
Table 69. Castration-resistant Prostate Cancer Drugs Market: Company Product Type Footprint
Table 70. Castration-resistant Prostate Cancer Drugs Market: Company Product Application Footprint
Table 71. Castration-resistant Prostate Cancer Drugs New Market Entrants and Barriers to Market Entry
Table 72. Castration-resistant Prostate Cancer Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 73. Global Castration-resistant Prostate Cancer Drugs Consumption Value (USD Million) by Type (2020-2025)
Table 74. Global Castration-resistant Prostate Cancer Drugs Consumption Value Share by Type (2020-2025)
Table 75. Global Castration-resistant Prostate Cancer Drugs Consumption Value Forecast by Type (2026-2031)
Table 76. Global Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2025)
Table 77. Global Castration-resistant Prostate Cancer Drugs Consumption Value Forecast by Application (2026-2031)
Table 78. North America Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2025) & (USD Million)
Table 79. North America Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2026-2031) & (USD Million)
Table 80. North America Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2025) & (USD Million)
Table 81. North America Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2026-2031) & (USD Million)
Table 82. North America Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 83. North America Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 84. Europe Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2025) & (USD Million)
Table 85. Europe Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2026-2031) & (USD Million)
Table 86. Europe Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2025) & (USD Million)
Table 87. Europe Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2026-2031) & (USD Million)
Table 88. Europe Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 89. Europe Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 90. Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2025) & (USD Million)
Table 91. Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2026-2031) & (USD Million)
Table 92. Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2025) & (USD Million)
Table 93. Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2026-2031) & (USD Million)
Table 94. Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value by Region (2020-2025) & (USD Million)
Table 95. Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value by Region (2026-2031) & (USD Million)
Table 96. South America Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2025) & (USD Million)
Table 97. South America Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2026-2031) & (USD Million)
Table 98. South America Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2025) & (USD Million)
Table 99. South America Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2026-2031) & (USD Million)
Table 100. South America Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 101. South America Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 102. Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2025) & (USD Million)
Table 103. Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2026-2031) & (USD Million)
Table 104. Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2025) & (USD Million)
Table 105. Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2026-2031) & (USD Million)
Table 106. Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 107. Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 108. Global Key Players of Castration-resistant Prostate Cancer Drugs Upstream (Raw Materials)
Table 109. Global Castration-resistant Prostate Cancer Drugs Typical Customers
LIST OF FIGURES
Figure 1. Castration-resistant Prostate Cancer Drugs Picture
Figure 2. Global Castration-resistant Prostate Cancer Drugs Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Type in 2024
Figure 4. Oral
Figure 5. Intravenous Injection
Figure 6. Others
Figure 7. Global Castration-resistant Prostate Cancer Drugs Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 8. Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Application in 2024
Figure 9. Hospital Picture
Figure 10. Specialty Clinic Picture
Figure 11. Others Picture
Figure 12. Global Castration-resistant Prostate Cancer Drugs Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 13. Global Castration-resistant Prostate Cancer Drugs Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 14. Global Market Castration-resistant Prostate Cancer Drugs Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)
Figure 15. Global Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Region (2020-2031)
Figure 16. Global Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Region in 2024
Figure 17. North America Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 18. Europe Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 19. Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 20. South America Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 21. Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 22. Company Three Recent Developments and Future Plans
Figure 23. Global Castration-resistant Prostate Cancer Drugs Revenue Share by Players in 2024
Figure 24. Castration-resistant Prostate Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024
Figure 25. Market Share of Castration-resistant Prostate Cancer Drugs by Player Revenue in 2024
Figure 26. Top 3 Castration-resistant Prostate Cancer Drugs Players Market Share in 2024
Figure 27. Top 6 Castration-resistant Prostate Cancer Drugs Players Market Share in 2024
Figure 28. Global Castration-resistant Prostate Cancer Drugs Consumption Value Share by Type (2020-2025)
Figure 29. Global Castration-resistant Prostate Cancer Drugs Market Share Forecast by Type (2026-2031)
Figure 30. Global Castration-resistant Prostate Cancer Drugs Consumption Value Share by Application (2020-2025)
Figure 31. Global Castration-resistant Prostate Cancer Drugs Market Share Forecast by Application (2026-2031)
Figure 32. North America Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Type (2020-2031)
Figure 33. North America Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Application (2020-2031)
Figure 34. North America Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Country (2020-2031)
Figure 35. United States Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 36. Canada Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 37. Mexico Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 38. Europe Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Type (2020-2031)
Figure 39. Europe Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Application (2020-2031)
Figure 40. Europe Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Country (2020-2031)
Figure 41. Germany Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 42. France Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 43. United Kingdom Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 44. Russia Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 45. Italy Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 46. Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Type (2020-2031)
Figure 47. Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Application (2020-2031)
Figure 48. Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Region (2020-2031)
Figure 49. China Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 50. Japan Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 51. South Korea Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 52. India Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 53. Southeast Asia Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 54. Australia Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 55. South America Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Type (2020-2031)
Figure 56. South America Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Application (2020-2031)
Figure 57. South America Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Country (2020-2031)
Figure 58. Brazil Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 59. Argentina Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 60. Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Type (2020-2031)
Figure 61. Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Application (2020-2031)
Figure 62. Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Country (2020-2031)
Figure 63. Turkey Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 64. Saudi Arabia Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 65. UAE Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 66. Castration-resistant Prostate Cancer Drugs Market Drivers
Figure 67. Castration-resistant Prostate Cancer Drugs Market Restraints
Figure 68. Castration-resistant Prostate Cancer Drugs Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. Castration-resistant Prostate Cancer Drugs Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
Table 1. Global Castration-resistant Prostate Cancer Drugs Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Castration-resistant Prostate Cancer Drugs Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Global Castration-resistant Prostate Cancer Drugs Consumption Value by Region (2020-2025) & (USD Million)
Table 4. Global Castration-resistant Prostate Cancer Drugs Consumption Value by Region (2026-2031) & (USD Million)
Table 5. Pfizer Company Information, Head Office, and Major Competitors
Table 6. Pfizer Major Business
Table 7. Pfizer Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 8. Pfizer Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 9. Pfizer Recent Developments and Future Plans
Table 10. Astellas Company Information, Head Office, and Major Competitors
Table 11. Astellas Major Business
Table 12. Astellas Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 13. Astellas Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 14. Astellas Recent Developments and Future Plans
Table 15. Janssen Company Information, Head Office, and Major Competitors
Table 16. Janssen Major Business
Table 17. Janssen Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 18. Janssen Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 19. AstraZeneca Company Information, Head Office, and Major Competitors
Table 20. AstraZeneca Major Business
Table 21. AstraZeneca Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 22. AstraZeneca Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 23. AstraZeneca Recent Developments and Future Plans
Table 24. Bayer Company Information, Head Office, and Major Competitors
Table 25. Bayer Major Business
Table 26. Bayer Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 27. Bayer Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 28. Bayer Recent Developments and Future Plans
Table 29. Hengrui Company Information, Head Office, and Major Competitors
Table 30. Hengrui Major Business
Table 31. Hengrui Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 32. Hengrui Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 33. Hengrui Recent Developments and Future Plans
Table 34. CTTQ Company Information, Head Office, and Major Competitors
Table 35. CTTQ Major Business
Table 36. CTTQ Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 37. CTTQ Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 38. CTTQ Recent Developments and Future Plans
Table 39. Sanofi Company Information, Head Office, and Major Competitors
Table 40. Sanofi Major Business
Table 41. Sanofi Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 42. Sanofi Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 43. Sanofi Recent Developments and Future Plans
Table 44. Hansoh Company Information, Head Office, and Major Competitors
Table 45. Hansoh Major Business
Table 46. Hansoh Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 47. Hansoh Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 48. Hansoh Recent Developments and Future Plans
Table 49. Clovis Oncology Company Information, Head Office, and Major Competitors
Table 50. Clovis Oncology Major Business
Table 51. Clovis Oncology Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 52. Clovis Oncology Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 53. Clovis Oncology Recent Developments and Future Plans
Table 54. Zhendong Pharmaceutical Company Information, Head Office, and Major Competitors
Table 55. Zhendong Pharmaceutical Major Business
Table 56. Zhendong Pharmaceutical Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 57. Zhendong Pharmaceutical Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 58. Zhendong Pharmaceutical Recent Developments and Future Plans
Table 59. Merck Company Information, Head Office, and Major Competitors
Table 60. Merck Major Business
Table 61. Merck Castration-resistant Prostate Cancer Drugs Product and Solutions
Table 62. Merck Castration-resistant Prostate Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 63. Merck Recent Developments and Future Plans
Table 64. Global Castration-resistant Prostate Cancer Drugs Revenue (USD Million) by Players (2020-2025)
Table 65. Global Castration-resistant Prostate Cancer Drugs Revenue Share by Players (2020-2025)
Table 66. Breakdown of Castration-resistant Prostate Cancer Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
Table 67. Market Position of Players in Castration-resistant Prostate Cancer Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 68. Head Office of Key Castration-resistant Prostate Cancer Drugs Players
Table 69. Castration-resistant Prostate Cancer Drugs Market: Company Product Type Footprint
Table 70. Castration-resistant Prostate Cancer Drugs Market: Company Product Application Footprint
Table 71. Castration-resistant Prostate Cancer Drugs New Market Entrants and Barriers to Market Entry
Table 72. Castration-resistant Prostate Cancer Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 73. Global Castration-resistant Prostate Cancer Drugs Consumption Value (USD Million) by Type (2020-2025)
Table 74. Global Castration-resistant Prostate Cancer Drugs Consumption Value Share by Type (2020-2025)
Table 75. Global Castration-resistant Prostate Cancer Drugs Consumption Value Forecast by Type (2026-2031)
Table 76. Global Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2025)
Table 77. Global Castration-resistant Prostate Cancer Drugs Consumption Value Forecast by Application (2026-2031)
Table 78. North America Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2025) & (USD Million)
Table 79. North America Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2026-2031) & (USD Million)
Table 80. North America Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2025) & (USD Million)
Table 81. North America Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2026-2031) & (USD Million)
Table 82. North America Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 83. North America Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 84. Europe Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2025) & (USD Million)
Table 85. Europe Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2026-2031) & (USD Million)
Table 86. Europe Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2025) & (USD Million)
Table 87. Europe Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2026-2031) & (USD Million)
Table 88. Europe Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 89. Europe Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 90. Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2025) & (USD Million)
Table 91. Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2026-2031) & (USD Million)
Table 92. Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2025) & (USD Million)
Table 93. Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2026-2031) & (USD Million)
Table 94. Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value by Region (2020-2025) & (USD Million)
Table 95. Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value by Region (2026-2031) & (USD Million)
Table 96. South America Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2025) & (USD Million)
Table 97. South America Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2026-2031) & (USD Million)
Table 98. South America Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2025) & (USD Million)
Table 99. South America Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2026-2031) & (USD Million)
Table 100. South America Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 101. South America Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 102. Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2020-2025) & (USD Million)
Table 103. Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value by Type (2026-2031) & (USD Million)
Table 104. Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2020-2025) & (USD Million)
Table 105. Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value by Application (2026-2031) & (USD Million)
Table 106. Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 107. Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 108. Global Key Players of Castration-resistant Prostate Cancer Drugs Upstream (Raw Materials)
Table 109. Global Castration-resistant Prostate Cancer Drugs Typical Customers
LIST OF FIGURES
Figure 1. Castration-resistant Prostate Cancer Drugs Picture
Figure 2. Global Castration-resistant Prostate Cancer Drugs Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Type in 2024
Figure 4. Oral
Figure 5. Intravenous Injection
Figure 6. Others
Figure 7. Global Castration-resistant Prostate Cancer Drugs Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 8. Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Application in 2024
Figure 9. Hospital Picture
Figure 10. Specialty Clinic Picture
Figure 11. Others Picture
Figure 12. Global Castration-resistant Prostate Cancer Drugs Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 13. Global Castration-resistant Prostate Cancer Drugs Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 14. Global Market Castration-resistant Prostate Cancer Drugs Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)
Figure 15. Global Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Region (2020-2031)
Figure 16. Global Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Region in 2024
Figure 17. North America Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 18. Europe Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 19. Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 20. South America Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 21. Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 22. Company Three Recent Developments and Future Plans
Figure 23. Global Castration-resistant Prostate Cancer Drugs Revenue Share by Players in 2024
Figure 24. Castration-resistant Prostate Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024
Figure 25. Market Share of Castration-resistant Prostate Cancer Drugs by Player Revenue in 2024
Figure 26. Top 3 Castration-resistant Prostate Cancer Drugs Players Market Share in 2024
Figure 27. Top 6 Castration-resistant Prostate Cancer Drugs Players Market Share in 2024
Figure 28. Global Castration-resistant Prostate Cancer Drugs Consumption Value Share by Type (2020-2025)
Figure 29. Global Castration-resistant Prostate Cancer Drugs Market Share Forecast by Type (2026-2031)
Figure 30. Global Castration-resistant Prostate Cancer Drugs Consumption Value Share by Application (2020-2025)
Figure 31. Global Castration-resistant Prostate Cancer Drugs Market Share Forecast by Application (2026-2031)
Figure 32. North America Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Type (2020-2031)
Figure 33. North America Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Application (2020-2031)
Figure 34. North America Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Country (2020-2031)
Figure 35. United States Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 36. Canada Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 37. Mexico Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 38. Europe Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Type (2020-2031)
Figure 39. Europe Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Application (2020-2031)
Figure 40. Europe Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Country (2020-2031)
Figure 41. Germany Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 42. France Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 43. United Kingdom Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 44. Russia Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 45. Italy Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 46. Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Type (2020-2031)
Figure 47. Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Application (2020-2031)
Figure 48. Asia-Pacific Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Region (2020-2031)
Figure 49. China Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 50. Japan Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 51. South Korea Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 52. India Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 53. Southeast Asia Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 54. Australia Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 55. South America Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Type (2020-2031)
Figure 56. South America Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Application (2020-2031)
Figure 57. South America Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Country (2020-2031)
Figure 58. Brazil Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 59. Argentina Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 60. Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Type (2020-2031)
Figure 61. Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Application (2020-2031)
Figure 62. Middle East & Africa Castration-resistant Prostate Cancer Drugs Consumption Value Market Share by Country (2020-2031)
Figure 63. Turkey Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 64. Saudi Arabia Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 65. UAE Castration-resistant Prostate Cancer Drugs Consumption Value (2020-2031) & (USD Million)
Figure 66. Castration-resistant Prostate Cancer Drugs Market Drivers
Figure 67. Castration-resistant Prostate Cancer Drugs Market Restraints
Figure 68. Castration-resistant Prostate Cancer Drugs Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. Castration-resistant Prostate Cancer Drugs Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
